Leadership Team

Mr. Zettl founded ZYUS’ wholly owned subsidiary, Life Sciences Inc., in April 2018. Prior to becoming the President and CEO of ZYUS, Mr. Zettl was the founder of ZYUS Life Sciences Inc. and co-founder of Prairie Plant Systems Inc. in 1988 (“PPS”) and CanniMed Ltd. in 2013 and their parent company, CanniMed Therapeutics Inc. In 1991, Mr. Zettl led the development of CanniMed’s first biosecure underground growth chamber in Flin Flon, Manitoba. In February 2003, he founded SubTerra (and PPS’s second biosecure underground growth chamber) at White Pine, Michigan and, in 2004, acquired the mine site for conversion into a biopharmaceutical production facility. Under his leadership, both PPS and CanniMed Ltd. became the first two licensed producers of cannabis under the Marihuana for Medical Purposes Regulations made under the CDSA in 2013. In 2016, CanniMed was awarded a licence for the production and sale of medical cannabis oils and was acquired in March 2018 for approximately $1.2 billion, the largest acquisition of a cannabis company at the time. Mr. Zettl contributes to the community through his involvement as director of the Canadian Environmental Technology 114 Advancement Corporation – West, Chair of Harvest Community Inc., a non-profit assisting people with intellectual disabilities, and past Chair of Ag-West Bio Inc., an organization supporting growth in the agricultural biotechnology industry. He has also been the chairman of the board of P.M. Power Group Inc., a company owned by PPS, since 2016. In 2014, Mr. Zettl was awarded the Ernst and Young Entrepreneur of the Year Award for the Prairies Business-to- Consumer category. Mr. Zettl received a Bachelor of Science in Agriculture degree with distinction from the University of Saskatchewan. 

Mr. Carpenter, BA (Economics), MBA, CFA, has more than 20 years of investment experience, spanning both the buy and sell-side. He had spent the last ten years in agriculture equity research, where he was a Brendan Wood Top Gun-ranked analyst and StarMine Award recipient. Prior to joining ZYUS in 2018, Mr. Carpenter worked as a Managing Director for both ATB Capital Markets (formerly AltaCorp Capital) from 2017 to 2018 and Canaccord Genuity from 2008 to 2015. Mr. Carpenter received his Bachelor of Arts from Yale University and his Masters of Business Administration from the University of Toronto.

Mr. Hyshka, B. Comm (Finance) has more than 20 years of experience as a business and finance leader in the life sciences space.  He has extensive experience establishing and scaling high-growth companies and a proven track record in raising capital.  Throughout his career, he has successfully raised over $75 million in Canada for different small to mid-size enterprises in the agriculture, medical device and therapeutics industries.

Dr. Marks de Chabris is an Ontario based physician with expertise in Pain Medicine and Addiction Medicine. A graduate of McGill University Medical School, he has been certified by the College of Family Physicians of Canada in Family Medicine, Emergency Medicine and Addiction Medicine and operated his private practice since 2006. His practice is concentrated in Pain Medicine and Addiction Medicine as has a coveted Focused Practice Designation by the Ontario Medical Association. In 2012 he established and continues to run one of only three Chronic Pain Management centers in northern Ontario.

Dr. Marks de Chabris is a Diplomate of the American Academy of Pain Management and the Canadian Academy of Pain Management and a Diplomate of the American Board of Addiction Medicine. He has been a Mentor in Addiction Medicine and Pain Medicine for the Ontario College of Family Physicians, a Fellow of the Canadian College of Family Physicians, a Medical Assessor and Clinical Supervisor for the College of Physicians and Surgeons of Ontario, an Independent Medical Examiner, and an Assistant Professor at the Northern Ontario School of Medicine. Dr. Marks de Chabris is recognized by the Ontario Superior Court as an Expert in Pain Management and Addiction Medicine.

Since joining ZYUS as Chief Medical Officer in 2019, Dr. Marks de Chabris has brought his 30 years of expertise to work with the clinical development team in conducting the landmark Phase 1 Trichomylin and HOPE trial. He also chairs the ZYUS’ Clinical Advisory Committee and spearheads the company’s Healthcare Practitioner Education Program.

Mr. Livingstone holds a Bachelor of Science in Pharmacy and a Master of Science in Clinical Pharmacy, both from the University of Saskatchewan. Scott has a proven track record of operational success in both public and private healthcare sectors, including hospital and community pharmacy practice, social sector policy and health care informatics. Prior to joining ZYUS, Mr. Livingstone served as the CEO of the Saskatchewan Health Information Network (now eHealth Saskatchewan), President and CEO of the Saskatchewan Cancer Agency, chair of both the National Steering Committee and the Saskatchewan Provincial Advisory Committee for the Pan Canadian Oncology Drug Review, and the inaugural President and CEO of the Saskatchewan Health Authority. These leadership positions have enabled Mr. Livingstone to play an active role in evidence-based assessment of oncology drugs, oncology drug safety and the sustainability of cancer control which, together with his passion for patient safety and patient-centered approach to care, makes Mr. Livingstone an ideal fit for ZYUS and its clinical research initiatives.